Market Newsdesk

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ: AFIB). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Acutus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On or around August 6, 2020, Acutus conducted its initial public offering (“IPO”), issuing 8,800,000 shares priced at $18.00 per share. Then, on March 19, 2021, analysts at both William Blair and JPMorgan downgraded Acutus’s stock, citing the Company’s weaker than expected revenue guidance and lack of clarity regarding progress on the commercialization of the Company’s AcQMap product. 

On this news, Acutus’s stock price fell $1.32 per share, or 7.84%, to close at $15.51 per share on March 19, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-acutus-medical-inc—afib-301262575.html

SOURCE Pomerantz LLP

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Elanco Animal Health Incorporated (“Elanco” or the “Company”) (NYSE: ELAN).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Elanco and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  

[Click here for information about joining the class action] 

On March 2, 2021, Midwest Center for Investigative Reporting and USA Today published a report linking the Company’s popular Seresto flea collar to the deaths of nearly 1,700 pets, as well as tens of thousands of other incidents of harm to pets and humans. 

On this news, Elanco’s stock price fell $2.78 per share, or 8.26%, over the following two trading sessions, to close at $30.87 per share on March 3, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]  
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-elanco-animal-health-incorporated—elan-301262566.html

SOURCE Pomerantz LLP

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Visa Inc. (“Visa” or the “Company”) (NYSE: V).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Visa and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On March 19, 2021, the Wall Street Journal published an article reporting that “[t]he Justice Department is investigating whether Visa Inc. is engaging in anticompetitive practices in the debit-card market, a probe that casts a cloud over a core part of its business.”  Specifically, the article reported that the investigation’s focus is “whether Visa, the largest U.S. card network, has limited merchants’ ability to route debit-card transactions over card networks that are often less expensive, according to people familiar with the matter.” 

On this news, Visa’s stock price fell $13.76 per share, or 6.24%, to close at $206.90 per share on March 19, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com 

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-visa-inc—v-301262558.html

SOURCE Pomerantz LLP

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of  Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ: FREQ). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Frequency and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On or around October 2, 2019, Frequency conducted its initial public offering (“IPO”), selling 6,000,000 shares of common stock priced at $14.00 per share. On March 23, 2021, Frequency issued a press release announcing topline, day-90 data from its FX-322 Phase 2a study (FX-322-202).  Frequency disclosed that “[t]he interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo.” 

On this news, Frequency’s stock price fell $28.30 per share, or 77.98%, to close at $7.99 per share on March 23, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]  
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of–frequency-therapeutics-inc—freq-301262573.html

SOURCE Pomerantz LLP

STOCKHOLM, April 6, 2021 /PRNewswire/ — The leading global hygiene and health company Essity is acquiring the distribution rights to the wound care technology Sorbact^® in Australia and New Zealand from the Australian company Bayport Brands. In 2020, sales of Sorbact^® in the region amounted to AUD 1.7m (approximately SEK 11m). 

“This acquisition underlines our ambition to accelerate growth in advanced wound care, where we showed good organic sales growth during the second half of 2020. It is also a good fit for our strategy to establish a stronger presence in Australia and New Zealand, where we – in addition to our successful Medical Solutions operations – are also in the final phase of the acquisition of Asaleo Care,” says Magnus Groth, President and CEO of Essity.

Sorbact^® is a clinically established innovation for advanced wound care, which is manufactured and marketed by Abigo Medical. Essity acquired 75% of Abigo Medical in February 2020. 

Sorbact^® is used in wound care products to prevent and treat infections. It does this using a natural mode of action that binds bacteria and fungi. Sorbact^® does not contain antiseptics or other toxic substances, which is positive for both the patient and the environment. 

For further information, please contact:

Per Lorentz

Vice President Corporate Communications
+46 8 788 52 51
[email protected] 

Johan Karlsson

Vice President Investor Relations
+46 8 788 51 30
[email protected] 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/essity/r/essity-acquires-distribution-rights-to-sorbact-in-australia-and-new-zealand,c3319753

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/essity-acquires-distribution-rights-to-sorbact-in-australia-and-new-zealand-301262606.html

SOURCE Essity

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Ionis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On March 22, 2021, post-market, Ionis issued a press release announcing that “its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington’s disease (HD).” Ionis specified that “[t]he decision was based on the results of a pre-planned review of data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). While there were no new or emerging safety signals identified for tominersen, the iDMC made its recommendation based on the investigational therapy’s potential benefit/risk profile for study participants.”

On this news, Ionis’s stock price fell $12.05 per share, or 21.66%, to close at $43.59 per share on March 23, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ionis-pharmaceuticals-inc—ions-301262557.html

SOURCE Pomerantz LLP

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of SoftBank Group Corporation  (“SoftBank” or the “Company”) (OTCMKTS: SFTBY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether SoftBank and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On March 24, 2021, the short seller research site PlainSite posted a letter from the U.S. Securities and Exchange Commission (“SEC”) on Twitter, in response to a December 2020 Freedom of Information Act (“FOIA”) request, which revealed that SoftBank was the subject of an ongoing SEC investigation. The initial FOIA request sought information related to SoftBank’s trading of the securities of companies controlled by SoftBank Chief Executive Officer Masayoshi Son. 

On this news, SoftBank’s stock price fell $2.30 per share, or 5.12%, to close at $42.65 per share on March 24, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

Contact:

Robert S. Willoughby

Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-softbank-group-corporation—sftby-301262588.html

SOURCE Pomerantz LLP

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of BlueCity Holdings Limited (“BlueCity” or the “Company”) (NASDAQ: BLCT).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether BlueCity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On or around July 8, 2020, BlueCity conducted its initial public offering, issuing 5,300,000 American Depositary Shares (“ADSs”) priced at $16.00 per ADS.  Then, on March 23, 2021, BlueCity issued a press release announcing its results for the fourth quarter of 2020.  Among other results, BlueCity announced revenue of $42.7 million, missing consensus estimates by $3.92 million. 

On this news, BlueCity’s ADS price fell $2.15 per ADS, or 26.71%, over the following two trading sessions, to close at $8.92 per ADS on March 24, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]  
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-bluecity-holdings-limited—blct-301262556.html

SOURCE Pomerantz LLP

LOD, Israel, April 6, 2021 /PRNewswire/ — Ethernity Networks (AIM: ENET.L), a leading supplier of data processing offload solutions on programmable hardware for accelerating telco/cloud networks, announced today that it has started receiving production orders for its ENET Flow Processor FPGA systems-on-chip (SoCs) by Tarana Wireless, an American wireless broadband solution manufacturer. Ethernity FPGA SoCs provide complete IP networking functionality, including critical traffic management features, for Tarana’s ground-breaking Gigabit1 (G1) product.

Following a contract between Tarana and Ethernity signed in 2017, Ethernity has worked with Tarana and supported its development efforts, including multiple field trials, in bringing this innovative fixed mobile access product to mass adoption. Tarana is now fulfilling orders from service providers for large-scale commercial deployments of G1, requiring supply of 5,000 units of Ethernity’s ENET Flow Processor over the next 12 months. Further growth is expected in 2022.

Tarana has developed its unique radio access network technology from the ground up, including custom silicon for radio frequency and digital signal processing, specifically to address the significant shortcomings of prior attempts at fixed wireless using technology repurposed from other applications (i.e. indoor Wi-Fi and mobile cellular). Given its purpose-built design and numerous genuine industry firsts in RF signal processing, G1 can provide fiber-class service from installations on existing cellular tower assets in non-line-of-sight conditions — and in unlicensed spectrum — with performance and network economics 3x better than 5G for fixed broadband.

Ethernity has provided Tarana its equally unique silicon-tuned software, which, thanks to the efficiency of the ENET Flow Processor design, fits into low-cost FPGAs. Working in concert with Tarana’s radio technology in its tower-installed base nodes, the ENET Flow Processor provides advanced networking functions, traffic control, and management for up to 512 homes per ENET SoC.

“We are very pleased to see Tarana progressing with our ENET Flow Processor FPGA, through multiple field trials and now toward mass deployment of their product,” said David Levi, CEO of Ethernity Networks. “Our contribution to their G1 product helps carry intact their extremely high performance in the radio frequency domain into the IP domain, which we are confident will help this innovative technology gain additional traction with operators the world over. We are looking forward to supporting Tarana in their rapid commercial ramp.”

“Our collaboration with the Ethernity team has certainly made a significant contribution to our end-to-end system design,” noted Rakesh Tiwari, Tarana’s VP of Product Management. “Our ability to easily customize packet processing on the ENET platform to meet our application-specific needs has made it a superior choice over off-the-shelf ASIC-based switches.”

About Ethernity Networks

Ethernity Networks (AIM: ENET.L) provides innovative, comprehensive networking and security solutions on programmable hardware for accelerating telco/cloud networks. Ethernity’s FPGA logic offers complete Carrier Ethernet Switch Router data plane processing and control software with a rich set of networking features, robust security, and a wide range of virtual function accelerations to optimize telecommunications networks. Ethernity’s complete solutions quickly adapt to customers’ changing needs, improving time-to-market and facilitating the deployment of 5G, edge computing, and NFV.

About Tarana Wireless

Developed by a closely-knit team of 200+ seasoned engineers, Tarana’s patented and fundamental breakthroughs in radio access technology bring cellular wireless deployment simplicity to fiber-class fixed broadband for both mainstream and underserved markets, using both licensed and free, globally available, unlicensed spectrum. Tarana is headquartered in Milpitas, California, with additional research and development in Pune, India. For further information, please visit https://www.taranawireless.com

Ethernity Media and Analyst contact:
Kevin Tanzillo
Email: [email protected]
Tel: +1-903-865-1078   

For Tarana Wireless, Inc.: 
Steven Glapa, VP of Marketing
Tel: +1-408-351-4085

View original content:http://www.prnewswire.com/news-releases/ethernity-networks-powers-packet-processing-in-taranas-breakthrough-fixed-wireless-product-301262581.html

SOURCE Ethernity Networks